Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib With or Without Ramucirumab in MET Exon 14 Skipping Positive Stage IV or Recurrent NSCLC
NCT06031688Phase 2Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Aug 2024
- Primary completion
- May 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ramucirumab in non-small cell lung cancer (NSCLC), sponsored by SWOG Cancer Research Network. Started Aug 2024; status: recruiting.
02
Drugs
ramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06031688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06031688.